Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease (Q36906673)

17 August 2017

1 reference

title

Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease (English)

1 reference

17 August 2017

1 reference

Stephen D Miller

1 reference

17 August 2017

Danielle M Turley

series ordinal

1 reference

17 August 2017

Joseph R Podojil

series ordinal

1 reference

17 August 2017

publication date

10 August 2007

1 reference

Nature Reviews Immunology

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

665-677

1 reference

The many important facets of T-cell repertoire diversity

17 August 2017

cites work

1 reference

31 March 2020

1 reference

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

31 March 2020

1 reference

Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-Induced Anergy

31 March 2020

1 reference

Intravenous antigen administration as a therapy for autoimmune demyelinating disease

31 March 2020

1 reference

A view on beta cell transplantation in diabetes.

31 March 2020

1 reference

Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes

31 March 2020

1 reference

Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes.

31 March 2020

1 reference

CD4+CD25+ regulatory T cells generated in response to insulin B:9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells.

31 March 2020

1 reference

DNA immunization to prevent autoimmune diabetes

31 March 2020

1 reference

Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice

31 March 2020

1 reference

DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice.

31 March 2020

1 reference

Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

31 March 2020

1 reference

Late complications of immune deviation therapy in a nonhuman primate

31 March 2020

1 reference

Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85VVHFFKNIVTP96 in chronic progressive multiple sclerosis

31 March 2020

1 reference

An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide

31 March 2020

1 reference

Therapeutic potential of oral tolerance

31 March 2020

1 reference

Oral tolerance: mechanisms and therapeutic applications.

31 March 2020

1 reference

Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.

31 March 2020

1 reference

Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein

31 March 2020

1 reference

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

31 March 2020

1 reference

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

31 March 2020

1 reference

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

31 March 2020

1 reference

Oral tolerance: overview and historical perspectives

31 March 2020

1 reference

Current issues in the treatment of human diseases by mucosal tolerance

31 March 2020

1 reference

Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats

31 March 2020

1 reference

Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide

31 March 2020

1 reference

Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA

31 March 2020

1 reference

Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes

31 March 2020

1 reference

Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines

31 March 2020

1 reference

Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity

31 March 2020

1 reference

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

31 March 2020

1 reference

The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells

31 March 2020

1 reference

Administration of myelin basic protein-coupled spleen cells prevents experimental allergic encephalitis

31 March 2020

1 reference

Evolution of the T‐Cell Repertoire during the Course of Experimental Immune‐Mediated Demyelinating Diseases

31 March 2020

1 reference

Differential susceptibility of human T(h)1 versus T(h) 2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells

31 March 2020

1 reference

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

31 March 2020

1 reference

Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities

31 March 2020

1 reference

Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes

31 March 2020

1 reference

Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein

31 March 2020

1 reference

Antigen-Specific Tolerance as a Therapy for Experimental Autoimmune Encephalomyelitis

31 March 2020

1 reference

The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases

31 March 2020

1 reference

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE

31 March 2020

1 reference

31 March 2020

1 reference

Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.

31 March 2020

1 reference

CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

31 March 2020

1 reference

Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells

31 March 2020

1 reference

Inhibition of experimental autoimmune uveitis by retinal photoreceptor antigens coupled to spleen cells

31 March 2020

1 reference

Induction of Peripheral Tolerance with Peptide-Specific Anergy in Experimental Autoimmune Neuritis

31 March 2020

1 reference

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

31 March 2020

1 reference

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

31 March 2020

1 reference

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance

31 March 2020

1 reference

Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in Lewis rats

31 March 2020

1 reference

Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties

31 March 2020

1 reference

Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential

31 March 2020

1 reference

IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens

31 March 2020

1 reference

Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

31 March 2020

1 reference

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

31 March 2020

1 reference

An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis

31 March 2020

1 reference

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

31 March 2020

1 reference

Immunomodulation of experimental autoimmune encephalomyelitis with ordered peptides based on MHC-TCR binding motifs

31 March 2020

1 reference

Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells

31 March 2020

1 reference

Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial

31 March 2020

1 reference

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group

31 March 2020

1 reference

Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes

31 March 2020

1 reference

Cytokine profile and insulin antibody IgG subclasses in patients with recent onset Type 1 diabetes treated with oral insulin

31 March 2020

1 reference

Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes

31 March 2020

1 reference

Oral tolerance: therapeutic implications for autoimmune diseases

31 March 2020

1 reference

Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis

31 March 2020

1 reference

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

31 March 2020

1 reference

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

31 March 2020

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

31 March 2020

1 reference

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

31 March 2020

1 reference

Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope

31 March 2020

1 reference

Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis.

31 March 2020

1 reference

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

31 March 2020

1 reference

CD3-specific antibody-induced active tolerance: from bench to bedside

31 March 2020

1 reference

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

31 March 2020

1 reference

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

31 March 2020

1 reference

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

31 March 2020

1 reference

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

31 March 2020

1 reference

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

31 March 2020

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

31 March 2020

1 reference

A controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

31 March 2020

1 reference

Reactivation of JC virus and development of PML in patients with multiple sclerosis

31 March 2020

1 reference

Partners in transcription: NFAT and AP-1.

31 March 2020

1 reference

FOXP3 controls regulatory T cell function through cooperation with NFAT

31 March 2020

1 reference

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction.

31 March 2020

1 reference

31 March 2020

1 reference

GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells

31 March 2020

1 reference

Altered thymic positive selection and intracellular signals in Cbl-deficient mice

31 March 2020

1 reference

T-cell signalling and autoimmunity: molecular mechanisms of disease

31 March 2020

1 reference

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

31 March 2020

1 reference

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial

31 March 2020

1 reference

A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRI2153

1 reference

17 August 2017

1 reference